No Data
No Data
Phathom Pharmaceuticals | 10-Q/A: Quarterly report (Amendment)
Phathom Pharmaceuticals | 10-K/A: Annual report (Amendment)
Phathom Pharmaceuticals Insiders Benefit From Selling Stock At US$8.90
Despite the fact that Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) stock rose 13% last week, insiders who sold US$367k worth of stock in the previous 12 months are likely to be better off. Selling at
Craig-Hallum Initiates Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Craig-Hallum analyst Albert Lowe initiates coverage on $Phathom Pharmaceuticals(PHAT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average retur
Investors Tempted by Latest Meme-stock Rally Should See These Charts Before Jumping in
By Joseph Adinolfi Shares of heavily shorted stocks occasionally see face-ripping rallies, but they typically underperform boring benchmarks like the S&P 500 over time Shares of heavily shorted stoc
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Positive Market Outlook
No Data